IKNA Key Statistics, Chart & Performance
The current stock price of IKNA is 1.43 USD. In the past month the price increased by 6.72%. In the past year, price decreased by -15.88%.
IKNA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to IKNA. When comparing the yearly performance of all stocks, IKNA turns out to be only a medium performer in the overall market: it outperformed 47.83% of all stocks.
IKNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IKNA. No worries on liquidiy or solvency for IKNA as it has an excellent financial health rating, but there are worries on the profitability.
IKNA Financial Highlights
Over the last trailing twelve months IKNA reported a non-GAAP Earnings per Share(EPS) of -3.28. The EPS decreased by -121.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.79% | ||
| ROE | -39.1% | ||
| Debt/Equity | 0 |
IKNA Forecast & Estimates
IKNA Ownership
IKNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.35 | 984.41B | ||
| JNJ | JOHNSON & JOHNSON | 21.02 | 525.73B | ||
| MRK | MERCK & CO. INC. | 12.42 | 271.66B | ||
| PFE | PFIZER INC | 7.98 | 145.10B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.27 | 110.38B | ||
| ZTS | ZOETIS INC | 19.44 | 54.31B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.51 | 22.56B | ||
| VTRS | VIATRIS INC | 5.43 | 14.58B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.17 | 12.00B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.30B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 5.52B |
Related stock screener links
About IKNA
Company Profile
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. The company is headquartered in Boston, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.
Company Info
IKENA ONCOLOGY INC
50 Northern Ave.
Boston MASSACHUSETTS 02210 US
CEO: Mark Manfredi
Employees: 18
Phone: 18573438292
IKENA ONCOLOGY INC / IKNA FAQ
What does IKENA ONCOLOGY INC do?
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. The company is headquartered in Boston, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.
Can you provide the latest stock price for IKENA ONCOLOGY INC?
The current stock price of IKNA is 1.43 USD. The price increased by 4.38% in the last trading session.
What is the dividend status of IKENA ONCOLOGY INC?
IKNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IKNA stock?
IKNA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for IKENA ONCOLOGY INC?
IKENA ONCOLOGY INC (IKNA) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the PE ratio for IKNA stock?
IKENA ONCOLOGY INC (IKNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.28).